High-grade B-cell Lymphoma Clinical Trial
Official title:
DLBCL Interim Response Evaluation for Customised Therapy
The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.
This will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade B cell lymphoma Data will be integrated from 1. Clinical risk factors from the International Prognostic Index (IPI) 2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy 3. Serial ctDNA monitoring during treatment. 4. Radiological response imaging ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04555811 -
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
|
Phase 1 | |
| Not yet recruiting |
NCT05834426 -
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
|
||
| Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT06093841 -
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL
|
Phase 2 | |
| Recruiting |
NCT04300998 -
Study of CAR-T Therapy in Older Patients
|
||
| Recruiting |
NCT04796857 -
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
|
Phase 1/Phase 2 | |
| Completed |
NCT04933617 -
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
|
Phase 1 | |
| Terminated |
NCT04358458 -
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05621096 -
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT06287398 -
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
|
Phase 2 | |
| Recruiting |
NCT04594642 -
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04836507 -
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT04844086 -
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
|
Phase 1 | |
| Completed |
NCT04858568 -
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
|
||
| Recruiting |
NCT04855253 -
Study of E7777 Prior to Kymriah for R/R DLBCL
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04914741 -
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04067414 -
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
|
Phase 1 | |
| Terminated |
NCT03132584 -
Cyclophosphamide and Alemtuzumab In Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04476459 -
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
|
Phase 1/Phase 2 |